Are you considering the use of circulating tumor DNA or circulating tumor cell count to make clinical decisions in the adjuvant setting after colon cancer resection?
Has the new data with the Natera assay from Reinert T et al in JAMA Oncology May 2019 changed your practice?
Community PollStarted
Would you give adjuvant chemotherapy for a low risk stage II colon cancer (pT2N0 and no pathologic risk factors) patient if the ctDNA showed 1% APC mutation when you checked this at week 4 after surgery?
27 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Rutgers Cancer Institute of New Jersey
Answered on
Circulating tumor DNA (ctDNA) has become commercially available with several NGS panel sequencing 70-100 genes. It is somewhat of interest in determining resistance to anti-EGFR drugs for advanced disease patients, as transient RAS mutations may emerge and then recede.
In the adjuvant setting, one st...
Join for free or sign in to see the full answer